| Literature DB >> 25859269 |
Huma Ali1, Savita Dixit1.
Abstract
To evaluate the chemopreventive potential of quercetin in an experimental skin carcinogenesis mouse model. Skin tumor was induced by topical application of 7, 12-dimethyl Benz (a) anthracene (DMBA) and Croton oil in Swiss albino mouse. Quercetin was orally administered at a concentration of 200 mg/kg and 400 mg/kg body weight daily for 16 weeks in mouse to evaluate chemopreventive potential. Skin cancer was assessed by histopathological analysis. We found that quercetin reduced the tumor size and the cumulative number of papillomas. The mean latent period was significantly increased as compared to carcinogen treated controls. Quercetin significantly decreased the serum levels of glutamate oxalate transaminase, glutamate pyruvate transaminase, alkaline phosphatase and bilirubin. It significantly increased the levels of glutathione, superoxide dismutase and catalase. The elevated level of lipid peroxides in the control group was significantly inhibited by quercetin. Futhermore, DNA damage was significantly decreased in quercetin treated mice as compared to DMBA and croton oil treated mice. The results suggest that quercetin exerts chemopreventive effect on DMBA and croton oil induced skin cancer in mice by increasing antioxidant activities.Entities:
Keywords: chemoprevention; papilloma; quercetin; skin carcinogenesis
Year: 2014 PMID: 25859269 PMCID: PMC4389114 DOI: 10.7555/JBR.29.20130025
Source DB: PubMed Journal: J Biomed Res ISSN: 1674-8301
Fig. 1H&E stained cross-sections of mouse skin.
A: Group I (water), B: Group II (water + DMBA + croton oil), C: Group III (quercetin 200 mg/kg+ DMBA + croton oil), D: Group IV (quercetin 400 mg/kg+ DMBA + croton oil). Arrow (→) shows damage in tissue.
Chemopreventive effect of quercetin on DMBA croton oil induced skin carcinogenesis in mice.
| Treatment | Body weight (g) | No. of papilloma | Tumor size (mm) | Average latent period | |
|---|---|---|---|---|---|
| Initial | Final | ||||
| Group I (normal) | 38.12±4.23 | 37.56±5.43 | |||
| Group II (control) | 26.26±2.16 | 22.75±11.24 | 10.16±5.03 | 2.06±0.37 | 10.10±5.17 |
| Group III (treated) | 29.57±1.18 | 26.15±12.88 | 1.50±1.04 | 0.93±0.24 | 13.10±0.76 |
| Group IV (treated) | 29.64±1.50 | 27.04±13.25 | 1.16±0.75 | 0.87±0.22 | 13.59±0.68 |
The lag between the application of the promoting agent and the appearance of 50% of tumors were determined. Average latent period = Σfx/n, f is the number of tumors appearing each week; x is the number of weeks and n is the total number of tumors.
Effect of quercetin on oxidative enzyme levels.
| Treatment | GSH μmol/mg protein | SOD μmol/mg protein | Catalase U/mg protein | LPO nmol/mg protein |
|---|---|---|---|---|
| Group I (normal) | 24.28±1.60 | 74.42±2.06 | 36.60±1.72 | 1.82±0.86 |
| Group II (control) | 8.02±0.96 | 59.59±2.15 | 5.97±1.07 | 4.82±1.71 |
| Group III (treated) | 23.69±3.23 | 70.34±9.93 | 12.79±5.76 | 3.00±0.21 |
| Group IV (treated) | 29.09±3.86 | 76.25±13.80 | 18.72±3.99 | 2.32±0.27 |
P < 0.05. GSH: glutathione; LPO, lipid peroxidase; SOD, superoxide dismutase.
Effect of quercetin on serum enzyme levels.
| Treatment | GOT IU/L | GPT IU/L | ALP IU/L | Bilurubbin mg/dL |
|---|---|---|---|---|
| Group I | 58.33±1.47 | 34.45±1.75 | 30.29±0.73 | 1.12±0.03 |
| Group II | 162.73±12.33 | 149.06±17.00 | 231.52±13.93 | 5.56±2.53 |
| Group III | 126.71±26.05 | 103.59±7.43 | 101.48±55.31 | 2.94±0.15 |
| Group IV | 114.68±11.53 | 82.62±18.54 | 68.85±7.05 | 2.50±0.43 |
P < 0.05.
Fig. 2DNA damage in lymphocytes after exposure to quercetin.
A: % tail DNA. B: Group I. C: Group II. D: Group III. Each value represents the mean ±S.E. of 3 experiments. *P < 0.05.